220998-10-7

220998-10-7 structure

Name: elomotecan
Chemical Name: Elomotecan
CAS Number: 220998-10-7
Molecular Formula: C₂₉H₃₂ClN₃O₄
Molecular Weight: 522.035
Catalog: Signaling Pathways Cell Cycle/DNA Damage Topoisomerase
Create Date: 2018-04-05 08:00:00
Modify Date: 2024-01-11 15:37:25
Elomotecan (BN 80927 free base) is a potent inhibitor of topoisomerases I and II. Elomotecan is a camptothecin analog belonging to the homocamptothecin family (hCPT). Elomotecan reduces the proliferation of different tumor cells with higher potency than other anticancer drugs of reference targeting topoisomerases I and II[1].

Name	Elomotecan
Synonyms	3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 9-chloro-5-ethyl-1,4,5,13-tetrahydro-5-hydroxy-10-methyl-12-[(4-methyl-1-piperidinyl)methyl]-, (5R)- unii-44ka9q75gt elomotecan (5R)-9-Chloro-5-ethyl-5-hydroxy-10-methyl-12-[(4-methyl-1-piperidinyl)methyl]-1,4,5,13-tetrahydro-3H,15H-oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione

Description	Elomotecan (BN 80927 free base) is a potent inhibitor of topoisomerases I and II. Elomotecan is a camptothecin analog belonging to the homocamptothecin family (hCPT). Elomotecan reduces the proliferation of different tumor cells with higher potency than other anticancer drugs of reference targeting topoisomerases I and II[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Cell Cycle/DNA Damage >> Topoisomerase
Target	Topoisomerase I Topoisomerase II
References	[1]. Trocóniz IF, et al. Population pharmacokinetic/pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, elomotecan (BN80927), in a Phase I dose finding study in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2012;70(2):239-250.